Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) - Forecast to 2027.

  • Report ID:MRHC - 104421
  • Pages: 160
  • Sep 2020
  • Formats*: PDF
  • Category: Healthcare
  • Delivery: 2 to 4 Hours

1.    Introduction
       1.1.    Market Definition
       1.2.    Market Ecosystem
       1.3.    Currency
       1.4.    Key Stakeholders

2.    Research Methodology
       2.1.    Research Process
        2.2.    Data Collection & Validation
                 2.2.1.    Secondary Research
                 2.2.2.    Primary Research
       2.3.    Market Assessment
                 2.3.1.    Market Size Estimation
                              2.3.1.1.    Bottom-Up Approach
                              2.3.1.2.    Top-Down Approach
                              2.3.1.3.    Growth Forecast
                 2.3.2.    Market Share Analysis
       2.4.    Assumptions for the Study
       2.5.    Limitations for the Study

3.    Executive Summary

4.    Market Insights
       4.1.    Introduction
       4.2.    Drivers
                 4.2.1.    Increasing Number of Chronic Diseases in All Age Groups
                 4.2.2.    Rising Use of Immunoglobulins in Therapeutic Areas
                 4.2.3.    Growing Number of Plasma Collecting Centers
       4.3.    Restraints
                 4.3.1.    High Cost and Restricted Reimbursement for Plasma Products
                 4.3.2.    Increasing Use of Recombinant Alternatives
       4.4.    Opportunity
                 4.4.1.    Growing Prevalence of Blood and Respiratory Disorders
       4.5.    Challenge
                 4.5.1.    Government Regulations in Developing Countries
       4.6.    Covid-19 Impact on Plasma Fractionation

5.    Plasma Fractionation Market, By Product
       5.1.    Introduction
       5.2.    Immunoglobulins
                 5.2.1.    Intravenous Immunoglobulins (IVIG)
                 5.2.2.    Subcutaneous Immunoglobulins (SCIG)
                 5.2.3.    Other Immunoglobulins
       5.3.    Albumin
       5.4.    Coagulation Factors
       5.5.    Protease Inhibitors
       5.6.    Others

6.    Plasma Fractionation Market, By Application
       6.1.    Introduction
       6.2.    Neurology
       6.3.    Immunology
       6.4.    Hematology
       6.5.    Critical Care
       6.6.    Hemato-Oncology
       6.7.    Rheumatology
       6.8.    Other Applications

7.    Plasma Fractionation Market, By End User
       7.1.    Introduction
       7.2.    Hospitals & Clinics
       7.3.    Clinical Research Laboratories
       7.4.    Academic Institutes       

8.    Plasma Fractionation Market, By Geography
       8.1.    Introduction
       8.2.    North America
                 8.2.1.    U.S.
                 8.2.2.    Canada
       8.3.    Europe
                 8.3.1.    Germany
                 8.3.2.    France
                 8.3.3.    U.K.
                 8.3.4.    Italy
                 8.3.5.    Spain
                 8.3.6.    Rest of Europe
       8.4.    Asia-Pacific
                 8.4.1.    China
                 8.4.2.    India
                 8.4.3.    Japan
                 8.4.4.    Rest of Asia Pacific
       8.5.    Latin America
       8.6.    Middle East & Africa

9.    Competitive Landscape
       9.1.    Introduction
       9.2.    Key Growth Strategies
       9.3.    Competitive Benchmarking
                 9.3.1.    Competitive Benchmarking – By Products
       9.4.    Market Share Analysis (2019)
                 9.4.1.    CSL Limited
                 9.4.2.    Grifols, S.A.
                 9.4.3.    Shire Plc (A Subsidiary of Takeda Pharmaceutical Company Limited)

10.    Company Profiles
         10.1.    CSL Limited
                     10.1.1.    Business Overview
                     10.1.2.    Financial Overview
                     10.1.3.    Product Portfolio
                     10.1.4.    Strategic Developments
                                   10.1.4.1.    Partnerships
                                   10.1.4.2.    Acquisition
                                   10.1.4.3.    Expansion
                                   10.1.4.4.    Approvals
         10.2.    Grifols, S.A.
                     10.2.1.    Business Overview
                     10.2.2.    Financial Overview
                     10.2.3.    Product Portfolio
                     10.2.4.    Strategic Developments
                                   10.2.4.1.    New Product Launches & Approvals
                                   10.2.4.2.    Agreements and Collaboration
                                   10.2.4.3.    Acquisitions
                                   10.2.4.4.    Expansion
         10.3.    Octapharma AG
                     10.3.1.    Business Overview
                     10.3.2.    Financial Overview
                     10.3.3.    Product Portfolio
                     10.3.4.    Strategic Developments
                                   10.3.4.1.    Approvals
         10.4.    Kedrion S.P.A.
                     10.4.1.    Business Overview
                     10.4.2.    Financial Overview
                     10.4.3.    Product Portfolio
                     10.4.4.    Strategic Developments
                                   10.4.4.1.    Approval
                                   10.4.4.2.    Agreements, Collaboration, and Partnership
                                   10.4.4.3.    Acquisition
         10.5.    Shire Plc (Subsidiary of Takeda Pharmaceutical Company Limited)
                     10.5.1.    Business Overview
                     10.5.2.    Financial Overview
                     10.5.3.    Product Portfolio
                     10.5.4.    Strategic Developments
                                   10.5.4.1.    Approval
                                   10.5.4.2.    Acquisition and Merger
                                   10.5.4.3.    New Product Launches & Development
                                   10.5.4.4.    Expansion
         10.6.    Biotest AG
                     10.6.1.    Business Overview
                     10.6.2.    Financial Overview
                     10.6.3.    Product Portfolio                     
                     10.6.4.    Strategic Developments
                                   10.6.4.1.    Agreement
                                   10.6.4.2.    Approval
                                   10.6.4.3.    Acquisition
                                   10.6.4.4.    Expansion
         10.7.    China Biologic Products Holdings, Inc.
                     10.7.1.    Business Overview
                     10.7.2.    Financial Overview
                     10.7.3.    Product Portfolio
                     10.7.4.    Strategic Developments
                                   10.7.4.1.    Approval
                                   10.7.4.2.    Expansion
                                   10.7.4.3.    Acquisition
         10.8.    Bio Products Laboratory (BPL) Ltd
                     10.8.1.    Business Overview
                     10.8.2.    Product Portfolio
                     10.8.3.    Strategic Developments
                                   10.8.3.1.    New Product Launch
         10.9.    Japan Blood Products Organization
                     10.9.1.    Business Overview
                     10.9.2.    Financial Overview
                     10.9.3.    Product Portfolio
         10.10.   Shanghai RAAS Blood Products Co., Ltd.
                     10.10.1.    Business Overview
                     10.10.2.    Financial Overview
                     10.10.3.    Product Portfolio
                     10.10.4.    Strategic Developments
                                     10.10.4.1. Approval

11.    Appendix
         11.1.    Questionnaire
         11.2.    Available Customization

List of Tables

Table 1    Global Plasma Fractionation Market: Impact Analysis of Market Drivers (2020–2027)
Table 2    Number of Persons Aged 65 Years or Over by Geographic Region (2019 Vs 2050)
Table 3    Global Number of New PID Cases by Age Group, by Region
Table 4    Worldwide Plasma Proteins Market by Product (Without Recombinant Factors), 2008-2016 (In %)
Table 5    U.S. and Europe: Plasma Collection Centers and Collections, 2015-2018
Table 6    Recent Openings of Plasma Centers, 2018-2020
Table 7    Global Plasma Fractionation Market: Impact Analysis of Market Restraint (2020–2027)
Table 8    Plasmapheresis Parameters
Table 9    Global Plasma Fractionation Market Size, by Product, 2018-2027 ($Million)
Table 10    Global Consumption of IgG, 2018-2026 (In Kg)
Table 11    Key Players offering Immunoglobulins
Table 12    Global Plasma-Derived Immunoglobulins Market Size, by Product, 2018-2027 ($Million)
Table 13    Global Plasma-Derived Immunoglobulins Market Size, by Country/Region, 2018-2027 ($Million)
Table 14    Comparison of IVIG and SCIG
Table 15    Some Commercially Available IVIG Products and Their Properties
Table 16    Global Plasma-Derived intravenous Immunoglobulins Market Size, by Country/Region, 2018-2027 ($Million)
Table 17    Some Commercially Available SCIG Products and Their Properties
Table 18    Global Plasma-Derived Subcutaneous Immunoglobulins Market Size, by Country/Region, 2018-2027 ($Million)
Table 19    Global Plasma-Derived Other Immunoglobulins Market Size, by Country/Region, 2018-2027 ($Million)
Table 20    Key Players offering Albumin
Table 21    Global Plasma-Derived Albumin Market Size, by Country/Region, 2018-2027 ($Million)
Table 22    Key Players offering Coagulation Factors
Table 23    Global Plasma-Derived Coagulation Factors Market Size, by Country/Region, 2018-2027 ($Million)
Table 24    Key Players offering Protease inhibitors
Table 25    Global Plasma-Derived Protease inhibitors Market Size, by Country/Region, 2018-2027 ($Million)
Table 26    Global Other Plasma-Derived Products Market Size, by Country/Region, 2018-2027 ($Million)
Table 27    Global Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 28    Key Vendors offering Plasma Derived Products for Neurology
Table 29    Global Plasma Fractionation Market Size for Neurology, by Country/Region, 2018-2027 ($Million)
Table 30    Key Players offering Products for Immunology
Table 31    Global Plasma Fractionation Market Size for Immunology, by Country/Region, 2018-2027 ($Million)
Table 32    Key Vendors offering Plasma Derived Products for Hematology
Table 33    Global Plasma Fractionation Market Size for Hematology, by Country/Region, 2018-2027 ($Million)
Table 34    Key Vendors offering Plasma Derived Products for Critical Care
Table 35    Global Plasma Fractionation Market Size for Critical Care, by Country/Region, 2018-2027 ($Million)
Table 36    Global Plasma Fractionation Market Size for Hemato-Oncology, by Country/Region, 2018-2027 ($Million)
Table 37    Global Plasma Fractionation Market Size for Rheumatology, by Country/Region, 2018-2027 ($Million)
Table 38    Key Players offering Products for Other Applications
Table 39    Global Plasma Fractionation Market Size for Other Applications, by Country/Region, 2018-2027 ($Million)
Table 40    Global Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 41    Global Plasma Fractionation Market Size for Hospitals & Clinics, by Country/Region, 2018-2027 ($Million)
Table 42    Few Plasma Products under Clinical Trials, 2016-2020
Table 43    Global Plasma Fractionation Market Size for Clinical Research Laboratories, by Country/Region, 2018-2027 ($Million)
Table 44    Global Plasma Fractionation Market Size for Academic institutes, by Country/Region, 2018-2027 ($Million)
Table 45    Global Plasma Fractionation Market Size, by Country/Region, 2018-2027 ($Million)
Table 46    North America: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 47    North America: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 48    North America: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 49    Monthly Distribution in Sales to the U.S. Market, 2019-20
Table 50    U.S.: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 51    U.S.: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 52    U.S.: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 53    Canada: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 54    Canada: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 55    Canada: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 56    Europe: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 57    Europe: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 58    Europe: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 59    Germany: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 60    Germany: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 61    Germany: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 62    LFB Plasma Demand, 2016-20
Table 63    France: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 64    France: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 65    France: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 66    U.K.: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 67    U.K.: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 68    U.K.: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 69    Italy’s Self Sufficiency in 2017
Table 70    Italy: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 71    Italy: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 72    Italy: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 73    Hemoderivatives Production
Table 74    Self Sufficiency for Plasma-Derived Products
Table 75    Spain: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 76    Spain: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 77    Spain: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 78    Rest of Europe: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 79    Rest of Europe: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 80    Rest of Europe: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 81    Asia-Pacific: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 82    Asia-Pacific: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)
Table 83    Asia-Pacific: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)
Table 84    China: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)
Table 85 China: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)    
Table 86 China: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)    
Table 87 India: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)    
Table 88 India: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)    
Table 89 India: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)    
Table 90 Japan IG Price (Domestic 2.5mg/50mg IVIG Product)    
Table 91 Domestic Production and Import of PDMPs    
Table 92 Japan: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)    
Table 93 Japan: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)    
Table 94 Japan: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)    
Table 95 Rest of Asia-Pacific: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)    
Table 96 Rest of Asia-Pacific: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)    
Table 97 Rest of Asia-Pacific: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)    
Table 98 Latin America: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)    
Table 99 Latin America: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)    
Table 100 Latin America: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)    
Table 101 Middle East and Africa: Immunoglobulins Market Size, by Type, 2018-2027 ($Million)    
Table 102 Middle East and Africa: Plasma Fractionation Market Size, by Application, 2018-2027 ($Million)    
Table 103 Middle East and Africa: Plasma Fractionation Market Size, by End User, 2018-2027 ($Million)    
Table 104 Recent Developments, by Company, 2016-2020    

List of Figures

Figure 1    Research Process
Figure 2    Key Secondary Sources
Figure 3    Primary Research Techniques
Figure 4    Key Executives interviewed
Figure 5    Breakdown of Primary interviews (Supply Side & Demand Side)
Figure 6    Market Size Estimation
Figure 7    Global Plasma Fractionation Market Size, by Product Type, 2020 Vs 2027($Million)
Figure 8    Global Plasma Fractionation Market Size, by Application, 2020-2027 ($Million)
Figure 9    Global Plasma Fractionation Market Size, by End User, 2020-2027 ($Million)
Figure 10 Plasma Fractionation Market, by Region
Figure 11 Market Dynamics
Figure 12 Number of Genes Identified with Inborn Errors of Immunity
Figure 13 Covid-19 Associated Hospitalization Data
Figure 14 IVIG/SCIG Usage by Country, 2008-2014-2018 (Kg per Million People)
Figure 15 Worldwide Distribution of Plasma Collection and Fractionation Centers, 2018
Figure 16 Comparison between Cost Structure of Plasma industry and Non-Plasma Pharmaceutical industry
Figure 17 Worldwide Plasma Derived and Recombinant Factor Viii Market, 2010-2020 (International Units in Millions)
Figure 18 Number of Conditions and Prevalence Rate per 1,000 Population of Chronic Bronchitis, 2008-2019
Figure 19 Global Plasma Fractionation Market Size, by Product, 2020-2027 ($Million)
Figure 20 Global Demand for IgG, 2010-2026 (In Metric Tons)
Figure 21 IG Price in Japan, 2012-2018 (In $)
Figure 22 Global Share of IVIG & SCIG, 2019 and 2025 (%)
Figure 23 Global Albumin Consumption (Metric Tons), 2018-2026
Figure 24 Global Consumption of Plasma Derived Coagulation Factor VIII, 2014-2026 (International Units X Million)
Figure 25 Global Sales of C1 Esterase inhibitor (C1-Inh) For HAE, 2010-2016 (In $Million)
Figure 26 Global Plasma Fractionation Market Size, by Application, 2020-2027 ($Million)
Figure 27 Global Number of Orthopedic Surgeries, 2010-2020 (in Million)
Figure 28 Global Plasma Fractionation Market Size, by End User, 2020-2027 ($Million)
Figure 29 Government Funding for University Research (% of GDP), 2017
Figure 30 Global Plasma Fractionation Market Size, by Region, 2018-2027 ($Million)
Figure 31 North America: Plasma Fractionation Market Snapshot
Figure 32 U.S. Plasma Collection Centers, 2011-2018
Figure 33 Canada IG Use, Grams: 5 Year Trend
Figure 34 IVIG & SCIG Consumption by Country in Europe: 2011-2025
Figure 35 Europe Plasma Collection Centers: 2011-2017
Figure 36 Europe: Plasma Fractionation Market Snapshot
Figure 37 increase of Plasmapheresis in France: 2014-2017
Figure 38 Plasma for Fractionation, 2007-2017
Figure 39 Key Growth Strategies Adopted by Leading Players, 2016-2020
Figure 40 Plasma Fractionation: Competitive Benchmarking
Figure 41 Market Share Analysis: Plasma Fractionation industry, 2019
Figure 42 CSL Limited: Financial Overview (2019)
Figure 43 Grifols, S.A.: Financial Overview (2019)
Figure 44 Octopharma AG: Financial Overview (2019)
Figure 45 Kedrion S.P.A.: Financial Overview (2019)
Figure 46 Takeda Pharmaceutical Company Limited: Financial Overview (2019)
Figure 47 Biotest AG: Financial Overview (2019)
Figure 48 China Biologic Products Holdings, Inc.: Financial Overview (2019)
Figure 49 Mitsubishi Tanabe Pharma Corporation: Financial Overview (2019)
Figure 50 Shanghai RAAS Blood Products Co., Ltd.: Financial Overview (2019)        

COVID-19

This report provides pre & post COVID-19 market estimates

Download sample here

The plasma fractionation market is expected to grow at a CAGR of 7% from 2020 to 2027 to reach $41.4 billion by 2027. Plasma-derived products from plasma fractionation have therapeutic effects, which are employed for the treatment of various disorders. For instance, coagulation factor VIII, which is a plasma derivative, is used for the treatment and prophylaxis of hemophilia. Furthermore, it is also employed to stop excessive blood loss during surgical procedures. Similarly, immunoglobulins are employed in the treatment of primary and secondary immune deficiencies. Factors such as the rising use of immunoglobulins in therapeutic areas, increasing number of chronic diseases, and growing number of plasma collection centers are the drivers of the market.

However, the high cost & restricted reimbursement of plasma products and increasing use of recombinant alternatives are restricting the growth of this market to a certain extent.

Impact of COVID-19 on the Plasma Fractionation Market

The current treatment of COVID-19 caused by novel coronavirus SARS-CoV-2 has been limited to general supportive care, with the provision of critical care as no approved therapies or vaccines are available. Recently, plasma therapy is being adopted by many countries against coronavirus. Convalescent plasma treatment involves injecting the COVID-19 patient with convalescent sera of people who have recovered from the infection recently. The patient cured of the disease will have antibodies against the coronavirus, according to the report of the WHO-China Joint Mission on COVID-19. The serum of COVID-19 cured individuals has virus-neutralizing antibodies, which can act as a passive antibody therapy. It is called the convalescent sera of COVID-19. This convalescent serum can be collected by two ways—using routine blood withdrawal followed by a centrifuge technique and using an apheresis machine/cell separator machine. Various companies are moving towards developing effective treatment against COVID-19, as no effective treatment is yet found against this novel virus. For instance:

  • Kedrion Biopharma (Italy) started the development of a plasma-derived therapy for treating the COVID-19 virus. The company is working in close collaboration with hospitals from some of the most hard-hit regions of Italy.
  • Grifols, S.A. (Spain) is collecting a blood product from recovered COVID-19 patients to develop a possible treatment for the coronavirus disease. The company is screening volunteer donors and will use their plasma to produce hyperimmune globulin. The product with a high concentration of COVID-19 antibodies could be used to treat the virus if it proves effective.
  • Octapharma AG (Switzerland) launched a special project team to explore new therapies for COVID-19. The company also announced that it has also joined other leaders in plasma fractionation in a collaboration to develop a potential plasma-derived hyperimmune immunoglobulin therapy for treating COVID-19.
  • Virchow Biotech Pvt., Ltd. (India) was awarded funding support under the Department of Biotechnology (DBT)’s National Biopharma Mission to work on plasma therapy for COVID-19. The company has proposed to collect plasma from several human convalescent donors, in order to prepare a standardized immunoglobulin enriched in anti-COVID antibodies with a specific titer.

As COVID-19 cases are increasing and no specific treatment is yet available, plasma-derived immunoglobulin will play an important role in the treatment of the disease, thus creating a positive impact on the growth of the plasma fractionation market.

Plasma Fractionation Market

                                                  Click here to: Get Free Sample Pages of this Report

Key Findings of the Global Plasma Fractionation Market Study:

In 2020, the immunoglobulins segment estimated to dominate the global plasma fractionation market

Based on product type, the immunoglobulins segment is estimated to command the largest share of the overall plasma fractionation market in 2020. The large share can be attributed to the expanded use of immunoglobulins for various indications like primary or chronic immune deficiency.

In 2020, the neurology segment estimated to account for the largest share of the plasma fractionation market

Based on application, the neurology segment is estimated to command the largest share of the overall plasma fractionation market in 2020. A surge in neurological disorders, the need for plasma-derived products for treating disorders, and are the drivers for this application segment.

In 2020, the hospitals & clinics segment is estimated to dominate the overall plasma fractionation market

On the basis of end user, the hospitals and clinics segment is estimated to command the largest share of the overall plasma fractionation market in 2020. The growing need for therapies for immunodeficiency disorders, growing number of hospitals & healthcare expenditure, and rising consumption of plasma-derived products by hospitals & clinics are some of the major factors driving the growth of this segment.

Asia-Pacific: Fastest Growing Market

In 2020, the North American market is estimated to account for the largest share of the global plasma fractionation market. On the other hand, Asia-Pacific is expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of the APAC plasma fractionation market are rising consumption of plasma-derived products, presence of leading players, contract fractionation agreements between countries, and programs for increasing the use of plasma and fractionation.

Key Players

The report includes the competitive landscape analysis based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the past four years. The key players profiled in the global plasma fractionation market are CSL Limited (Australia), Grifols, S.A. (Spain), Octopharma AG (Switzerland), Kedrion S.P.A. (Italy), Shire plc (U.K.), Biotest AG (Germany), China Biologic Products Holdings, Inc. (China), Bio Products Laboratory Ltd (U.K.), Japan Blood Products Organization (Japan), and Shanghai RAAS Blood Products Co., Ltd. (China).

Scope of the Report:

Plasma Fractionation Market, by Product

  • Immunoglobulins
    • Intravenous Immunoglobulins
    • Subcutaneous Immunoglobulins
    • Others
  • Coagulation Factors
  • Albumin
  • Protease Inhibitors
  • Others

Plasma Fractionation Market, by Application

  • Immunology
  • Hematology
  • Neurology
  • Critical Care
  • Hemato-Oncology
  • Rheumatology
  • Others

Plasma Fractionation Market, by End User

  • Hospitals& Clinics
  • Clinical Research Laboratories
  • Academic Institutes

Plasma Fractionation Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key questions answered in the report:

The global plasma fractionation market covers the market size & forecasts various plasma fractionated products used in the healthcare sector. The plasma fractionation market studied in this report involves the value analysis of various segments and subsegments of plasma fractionated products at the regional and country level.
The plasma fractionation market is expected to grow at a CAGR of 7% from 2020 to 2027 to reach $41.4 billion by 2027.
The immunoglobulins segment commanded the largest share in 2020. Moreover, the protease inhibitors segment is further expected to grow at the highest CAGR during the forecast period.
The neurology segment commanded the largest share of the in 2020. Moreover, this segment is further expected to grow at the fastest CAGR during the forecast period.
The hospitals and clinics segment is projected to register the fastest CAGR during the forecast period, owing to the growing admissions in hospitals and clinics for disease treatment.
The rising use of immunoglobulins in therapeutic areas, increasing number of chronic diseases, and growing number of plasma collection centers are the main driving factors. The growing prevalence of blood and respiratory disorders is expected to offer significant growth opportunities for market players during the forecast period.
The key companies operating in the global plasma fractionation market are CSL Limited, Grifols, S.A., Octopharma AG Kedrion S.P.A. Shire plc, Biotest AG, China Biologic Products Holdings, Inc., Bio Products Laboratory Ltd, Japan Blood Products Organization, and Shanghai RAAS Blood Products Co., Ltd.
The emerging economies like China and India are projected to offer significant growth opportunities for vendors in this market, with increasing adoption of plasma-derived products for the treatment of various diseases, such as COVID-19.
This website is secure and we do not share your personal information with any third party. Privacy Policy
Tags: Healthcare
Download Free Sample